Show simple item record

Psychosis in Alzheimer's Disease

dc.contributor.authorBallard, C
dc.contributor.authorKales, HC
dc.contributor.authorLyketsos, C
dc.contributor.authorAarsland, D
dc.contributor.authorCreese, B
dc.contributor.authorMills, R
dc.contributor.authorWilliams, H
dc.contributor.authorSweet, RA
dc.date.accessioned2020-10-29T12:04:54Z
dc.date.issued2020-10-13
dc.description.abstractPURPOSE OF REVIEW: To review the incidence, treatment and genetics of psychosis in people with mild cognitive impairment (MCI) and Alzheimer's disease (AD). RECENT FINDINGS: Psychosis in Alzheimer's disease (AD) has an incidence of ~ 10% per year. There is limited evidence regarding psychological interventions. Pharmacological management has focused on atypical antipsychotics, balancing modest benefits with evidence of long-term harms. The 5HT2A inverse agonist pimavanserin appears to confer benefit in PD psychosis with initial evidence of benefit in AD. Cholinesterase inhibitors give modest benefits in DLB psychosis. The utility of muscarinic agonists, lithium, glutamatergic and noradrenergic modulators needs further study. Recent work has confirmed the importance of psychosis in MCI as well as AD. The lack of evidence regarding psychological therapies is an urgent knowledge gap, but there is encouraging evidence for emerging pharmacological treatments. Genetics will provide an opportunity for precision medicine and new treatment targets.en_GB
dc.identifier.citationVol. 20, article 57en_GB
dc.identifier.doi10.1007/s11910-020-01074-y
dc.identifier.urihttp://hdl.handle.net/10871/123403
dc.language.isoenen_GB
dc.publisherSpringeren_GB
dc.relation.urlhttps://www.ncbi.nlm.nih.gov/pubmed/33048274en_GB
dc.rights© The Author(s) 2020. Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.en_GB
dc.subjectAlzheimer’s diseaseen_GB
dc.subjectFrequencyen_GB
dc.subjectImpacten_GB
dc.subjectMechanismsen_GB
dc.subjectNon-pharmacologicalen_GB
dc.subjectPharmacologicalen_GB
dc.subjectPsychosisen_GB
dc.titlePsychosis in Alzheimer's Diseaseen_GB
dc.typeArticleen_GB
dc.date.available2020-10-29T12:04:54Z
exeter.place-of-publicationUnited Statesen_GB
dc.descriptionThis is the final version. Available on open access from Springer via the DOI in this recorden_GB
dc.identifier.eissn1534-6293
dc.identifier.journalCurrent Neurology and Neuroscience Reportsen_GB
dc.rights.urihttps://creativecommons.org/licenses/by/4.0en_GB
dcterms.dateAccepted2020-09-07
rioxxterms.versionVoRen_GB
rioxxterms.licenseref.startdate2020-10-13
rioxxterms.typeJournal Article/Reviewen_GB
refterms.dateFCD2020-10-29T12:02:10Z
refterms.versionFCDVoR
refterms.dateFOA2020-10-29T12:04:59Z
refterms.panelAen_GB


Files in this item

Name:
Ballard2020_Article_PsychosisI ...
Size:
658.4Kb
Format:
PDF
View/Open

This item appears in the following Collection(s)

Show simple item record

© The Author(s) 2020. Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Except where otherwise noted, this item's licence is described as © The Author(s) 2020. Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.